Vascular Closure Device Market Analysis & Forecast: 2025-2032

Vascular Closure Device Market Analysis & Forecast- 2025-2032

Vascular Closure Device Market size is estimated to be valued at USD 1,533.6 Mn in 2025 and is expected to reach USD 2,321.2 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of6.1% from 2025 to 2032.

Key Takeaways

• By Product Type, the Passive Vascular Closure Devices segment is projected to dominate the global vascular closure device market with a 50% market share in 2025, owing to its simplicity, lower complication rates, and widespread clinical use.
• By Region, North America is forecasted to lead the global vascular closure device market outlook, capturing a 38.5% share in 2025, driven by high procedural volumes, advanced healthcare infrastructure, and favorable reimbursement policies.

Market Overview

The Vascular Closure Devices Market is witnessing significant growth due to several driving factors. A rising number of interventional procedures—such as over 1 million cardiac catheterizations annually in the U.S.—is increasing demand for effective hemostasis solutions. Active closure devices like Perclose ProGlide and Angio-Seal VIP are gaining popularity as they enable early ambulation and same-day discharge, particularly beneficial in outpatient and ambulatory surgical settings.

For instance, a study published in the Journal of Invasive Cardiology found that patients using suture-mediated closure devices ambulated within 2 hours post-procedure compared to 6 hours with manual compression. Hospitals favor these devices for improving patient turnover and comfort.

Current Events and Its Impact on the Vascular Closure Devices Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Reimbursement plays a key role in the adoption of vascular closure devices (VCDs) globally. Various coding systems support coverage, including ICD-10-PCS codes for vascular occlusion procedures, CPT codes 37191 and 37192 for intravascular filter insertions, HCPCS code G0269 for occlusive device placement, and DRG codes 252–254 classifying vascular procedures by complication severity.

In the U.S., CMS sets reimbursement rates and coverage policies, influencing private insurers. Medicare covers 80% of VCD costs under Part B, with an estimated annual spend of $75 million. Private insurers cover 70-90%, with about $150 million spent annually.

In Europe, the UK’s NICE guides VCD use, with the NHS fully covering approved devices (~£25 million annually). Germany’s Federal Joint Committee (G-BA) governs reimbursement under Statutory Health Insurance, covering 90% of costs with €40 million annual spending.

Japan’s National Health Insurance reimburses 70-90% of VCD costs, spending roughly ¥3 billion annually.

CMS reimburses CPT codes 37191 and 37192 at approximately $2,553 and $1,716 respectively (2021). These reimbursement structures promote VCD use by ensuring cost coverage across major healthcare systems.

Segmental Insights

To learn more about this report, Download Free Sample

Vascular Closure Device Market Insights, By Product Type

Based on product type, the passive vascular closure devices segment is expected to dominate the global vascular closure device market with a 50.0% market share in 2025. This dominance is attributed to their ease of use, compatibility with standard femoral artery access procedures, and low procedural complexity.

Passive devices—including manual compression aids, bandages, and sandbags—enable natural clot formation without requiring active deployment steps, making them a preferred choice across high-volume healthcare settings.

Unlike active vascular closure devices, which require insertion mechanisms or sutures, passive devices are more cost-effective and suitable for settings where procedural simplicity and patient throughput are priorities. Furthermore, they eliminate the risks associated with device misdeployment or infection linked to mechanical closure systems. Their popularity in European markets, where femoral access remains widely used, reinforces their global uptake.

Regional Insights

To learn more about this report, Download Free Sample

North America Vascular Closure Device Market Analysis and Trends

North America is projected to lead the global vascular closure device market with 38.50% share in 2025, driven by advanced healthcare infrastructure, strong presence of key players, and rapid adoption of minimally invasive procedures. The U.S. dominates the regional market due to high procedural volumes and early integration of next-generation closure technologies among interventional cardiologists.

Leading manufacturers such as Abbott, Terumo, and Cardinal Health continue to invest in R&D and introduce innovative devices tailored to physician preferences. These efforts, along with favorable reimbursement structures and growing outpatient surgical trends, are strengthening market demand. However, challenges such as patent expirations and pricing pressure from insurance payers may impact long-term profitability.

Asia Pacific Vascular Closure Device Market Analysis and Trends

Asia Pacific is emerging as the second-largest and fastest-growing regional market for vascular closure devices, propelled by rising healthcare expenditures, expanding access to interventional procedures, and favorable government initiatives. China holds a dominant position in the region due to its large patient base and modernization of healthcare infrastructure under national policies.

India is also witnessing strong growth, driven by increasing medical tourism, cost-effective manufacturing, and rising procedural volumes. Global medtech leaders are expanding their footprint in these markets, offering localized products. Despite regulatory hurdles and workforce shortages, the region offers significant long-term growth potential.

Europe Vascular Closure Device Market Analysis and Trends

Europe’s vascular closure device market is led by the passive closure device segment, particularly in countries where femoral artery access remains standard practice. Passive devices—such as compression systems—are favored for their simplicity, cost-effectiveness, and compatibility with standard femoral access techniques.

As procedural safety and ease remain a priority across European healthcare systems, passive VCDs continue to dominate usage. Countries like Germany, France, and the U.K. are major contributors, supported by established healthcare systems and physician familiarity with passive closure techniques.

Analyst View

• The vascular closure device market is poised to grow at a steady pace over the next five years. The rising prevalence of cardiovascular diseases and increasing number of cardiovascular interventions are the major drivers propelling the demand for vascular closure devices.
• As more minimally invasive procedures are performed, the need for reliable devices to achieve hemostasis will continue to rise.
• North America currently dominates the vascular closure device market owing to the high adoption of advanced medical technologies and availability of favorable reimbursement policies in the region.
• However, Asia Pacific is expected to be the fastest-growing market as countries like China and India significantly ramp up spending on healthcare and modernize their healthcare infrastructures.
• While improved reimbursement and rising awareness about newer technologies present significant opportunities, inadequate clinical evidence sometimes poses a challenge for widespread adoption of certain novel devices.
• Product recalls and safety concerns also act as a restraints at times. High device costs further restrict market potential in price-sensitive developing regions. Device manufacturers should focus on further innovations to introduce safer, simple to use, and more effective products.
• Gaining regulatory approvals in Asia and other emerging markets early will help companies leverage future growth opportunities.
• Developing strong partnerships with hospitals and physicians is also crucial for vascular closure device companies to solidify their presence.

Global Vascular Closure Device Market Drivers

Rising geriatric population

• The number of older people around the world keeps rising, and that steady climb is a big reason the market for vascular closure devices is growing. As bodies add years, the odds of heart trouble-coronary artery disease, peripheral vascular disease, stroke, and the like-go up, pushing doctors toward tests and treatments such as angiography or angioplasty. When those procedures are done, the little plugs or sutures that seal the opening in the artery-vascular closure devices-become key parts of after-care.
• These devices close the puncture quickly and securely so blood flow resumes without delay. For older patients, who might bleed longer because of age, medication, or other health issues, a fast seal cuts down the risk of bruising or large hematomas, speeds the return to normal circulation, and, in many cases, trims days off the hospital bill.
• As the population continues to gray, the operating rooms and catheter labs will keep filling up with seniors, and each procedure boosts the demand for VCDs. Responding to that wave,
• Vascular-device companies must track how older patients' requirements shift over time if they want to keep an edge in this crowded market.
• For example, by 2020 there were already more people worldwide aged 60 and up than there were children under 5. Between 2015 and 2050, the share of the global population that is over 60 will almost double, climbing from about 12 percent to around 22 percent.
• The absolute number of seniors is forecasted to rise from roughly one billion in 2020 to 1.4 billion in the near future. By mid-century the figure could hit 2.1 billion. Meanwhile, those aged 80 and above are projected to triple during the same span, reaching about 426 million.

The proliferation of angioplasty procedures

• One big reason the worldwide market for vascular closure devices keeps growing is the soaring number of angioplasty surgeries. Angioplasty-unclogging narrowed heart arteries-has become the go-to fix for ischemic heart disease, a top killer and life-altering condition. Demand keeps climbing because heart problems linked to poor diets, little exercise, smoking, and plain aging are showing up more than ever.
• During an angioplasty, VCDs are vital because they seal the puncture in the artery quickly and securely. That speedy closure cuts the wait for firm bleeding control, lets patients get up sooner, shortens the overall hospital stay, and boosts a hospitals workflow, making the procedure better for patients and the bottom line.
• Healthcare teams appreciate that vascular closure devices (VCDs) enhance patient comfort while cutting the odds of bleeding, hematomas, and pseudoaneurysms, so the tools are now standard in many labs. Beyond those clinical wins, VCDs let people get back on their feet faster, a core aim of patient-centered care.
• As interventional cardiology moves forward, angioplasties are often done with large-bore catheters, and that shift calls for next-generation VCDs built to handle bigger sheaths. Devices designed for these demanding cases should open fresh market avenues.
• At the same time, hospitals prize lower readmission rates and better overall results, and reliable closure tools are seen as key to those targets. In response, manufacturers are doubling down on R&D to meet growing clinical and economic needs. Therefore, the surge in angioplasty volumes will keep driving the VCD sector, and that momentum is expected to last for years to come.

The increasing prevalence of in cardiovascular disease (CVD) incidence

• The increasing prevalence of cardiovascular disease (CVD) incidence globally is a significant factor driving the demand for vascular closure devices. The growth in the number of patients undergoing angiographic procedures, such as angioplasty, is directly proportional to the prevalence of cardiovascular conditions like coronary artery disease, stroke, heart failure, and peripheral arterial disease. These conditions often require diagnostic and interventional procedures that necessitate puncturing of blood vessels, where vascular closure devices (VCDs) are crucial. VCDs offer several advantages in post-procedural care by providing immediate hemostasis, reducing time to ambulation, and leading to improved patient outcomes. They mitigate potential complications, such as bleeding at the puncture site, which can lead to prolonged hospital stays and increased healthcare costs.
• Furthermore, as patients seek shorter recovery times and reduced hospitalization, VCDs align well with these preferences, supporting less invasive procedures with quicker recovery. The demand is also supported by the rise in minimally invasive surgeries being performed, which are becoming the standard of care for many cardiovascular interventions. Providers prefer these devices over traditional manual compression as they can significantly reduce the time required for the artery to close, ultimately leading to increased patient turnover and more efficient use of healthcare resources.
• To meet this growing demand, manufacturers are focusing on innovation, creating devices that are easier to use, more efficient, and compatible with various vascular procedures. The development of advanced materials and techniques also promises to enhance the safety profiles of these devices.
• However, as a market research analyst, it's crucial to monitor potential market restraints such as the availability of alternative wound closure methods, costs associated with VCDs, and reimbursement scenarios that vary across different regions. Considering these dynamics, it's evident that the increasing incidence of cardiovascular diseases is a primary driver for the vascular closure devices market, as they directly influence the volume of relevant surgical procedures performed.
•  To capitalize on this growing market, manufacturers will need to focus on innovation, addressing cost and reimbursement challenges, and aligning with the trends in healthcare towards less invasive and more patient-centered care.

Increasing demand for minimally invasive surgeries

• The increasing demand for minimally invasive surgeries (MIS) is definitely a key factor propelling the global vascular closure device market forward. As healthcare continues to advance towards techniques that emphasize patient comfort and reduce recovery time, MIS has become increasingly popular. This trend has a direct positive impact on the VCD market, as these devices are integral to many minimally invasive cardiovascular procedures.
• During MIS, VCDs are used to close the small puncture made in the artery, typically in the groin or wrist, through which catheters and other devices are inserted. They offer a safer and more comfortable alternative to traditional methods, such as manual compression, by promoting faster hemostasis and reducing the risk of access site complications, like bleeding or hematoma formation. This enables patients to mobilize sooner and potentially results in shorter hospital stays and less post-procedural care. In addition to improving patient outcomes, VCDs aid hospitals in increasing procedural efficiency.
• By reducing the time clinicians spend managing the puncture site post-procedure, these devices enable healthcare professionals to treat more patients in less time, thereby optimizing the utilization of hospital resources. The increasing prevalence of cardiovascular diseases further underscores the need for efficient and effective MIS, which in turn drives the demand for VCDs.
•  As technology continues to evolve, manufacturers are developing a wider range of VCDs to cater to various patient anatomies and procedural requirements. Overall, the convergence of the MIS trend with the growth in cardiovascular conditions presents a robust opportunity for the expansion of the VCD market. To maximize this potential, continuous innovation and awareness of reimbursement landscapes are essential, as these factors will significantly influence the adoption rate and market growth.

Market Report Scope

Global Vascular Closure Device Market Opportunities

• Emerging economies with large patient pools: Newly developing economies in the Asia-Pacific and Latin America are definitely emerging as bright spots for the worldwide vascular closure device (VCD) market. These areas are building bigger hospital networks, spending more on health care, and seeing an uptick in lifestyle diseases that lead to heart trouble. As countries such as China, India, and Brazil move forward, an expanding middle class gains better access to clinics and is more willing to spend on its own health.
• At the same time, local governments are pushing reform, modernizing medical centers, and thus raising demand for cutting-edge tools like VCDs. On top of that, the health systems in these nations are becoming more sophisticated; more hospitals and outpatient facilities can now carry out complicated cardiac procedures. That growth is matched by a rising number of cardiologists and cath-lab staff trained in intervention work, making it easier to adopt and use VCDs. Not surprisingly, pharma and device firms see the promise and are moving in hard, setting up local distribution, running tailor-made trials, and launching teaching sessions for doctors and nurses.
• Breaking into these markets is no small feat; firms have to steer around a tangle of local rules and set prices that make sense given what each government is willing to pay. Business models that team up with neighborhood companies and tweak products so they really fit day-to-day care are the ones most likely to take root and flourish. Keeping these points in mind, the changing healthcare landscapes across emerging Asia-Pacific and Latin American countries now offer a rich garden of growth possibilities. By directing focused effort toward these regions and rolling out tailor-made plans, companies can tap into the huge promise offered by a swelling patient base and steadily improving medical services.
• The Increasing healthcare expenditure: Increasing healthcare expenditure is a powerful driver for the global vascular closure device market. As countries around the world allocate more resources to their healthcare systems, this financial influx helps to improve healthcare infrastructure, expand the availability of medical services, and increase access to advanced medical technologies, including VCDs.

Greater healthcare spending often correlates with better access to quality care, and this is particularly relevant for the treatment of cardiovascular diseases, which remain a leading cause of death globally. Investment in healthcare can lead to the acquisition of advanced medical devices, training of healthcare professionals, and improved patient care pathways.

In countries with rising healthcare budgets, both public and private hospitals may be more inclined to invest in VCDs, which can streamline the management of vascular access sites after procedures like angiography or percutaneous coronary intervention (PCI). The use of VCDs helps to reduce time to hemostasis, patient recovery time, and overall treatment costs by shortening hospital stays and reducing the need for additional medical intervention due to complications.

Moreover, as out-of-pocket healthcare expenditures decrease due to better funding of health services, patients may be more likely to undergo necessary medical procedures, which would further drive the demand for VCDs. This is especially important in emerging markets, where an increase in disposable income and healthcare funding is making previously unaffordable treatments more accessible.

From a market perspective, companies could leverage increasing healthcare investments by aligning with government initiatives that aim to improve cardiovascular care, forming partnerships with healthcare providers, and working on cost-effective solutions that do not compromise on quality and safety. With this knowledge, companies can better strategize capitalizing on increasing healthcare expenditures to drive the market.

• New product launches: New product launches are a significant opportunity that can drive the global vascular closure device market. As clinical needs evolve and technological advancements occur, manufacturers that innovate and introduce new VCDs can gain a competitive edge and tap into unmet medical demands. The introduction of new products often comes with improved features such as enhanced safety profiles, greater efficacy, easier usability, and reduced complication rates.

Additionally, new VCDs may cater to a broader range of procedures, including support for complex interventions involving large-bore sheaths or catering to patients with different anatomical challenges. When a new product is introduced, it not only enhances the treatment options available to clinicians but also provides an opportunity for medical facilities to improve their standard of care. This can lead to better patient outcomes and potentially lower the overall cost of cardiovascular care by reducing procedure time, hospital stay duration, and incidence of post-procedure complications.

Moreover, with each innovative product, manufacturers can expand their market presence and establish a reputation as a leader in the market. This can be particularly advantageous when establishing relationships with emerging markets, where healthcare infrastructure is improving, and the demand for quality medical devices is increasing. Constant innovation and refreshment of product lines also help in satisfying the regulatory requirements that may change over time, ensuring compliance with the latest safety standards.

In an industry where regulations are stringent and patient safety is paramount, staying updated with the latest trends and technology is crucial. From a strategic standpoint, companies in the market should invest in robust research and development (R&D) to facilitate the continuous introduction of differentiated products.

Global Vascular Closure Device Market Trends

• The utilization of bioabsorbable vascular closure devices

The utilization of bioabsorbable vascular closure devices is emerging as a significant trend and represents a promising opportunity within the market. These devices, which are designed to be absorbed by the body over time, are gaining attention for their potential to reduce the risk of infection, minimize inflammation, and improve patient comfort compared to non-absorbable counterparts.

Bioabsorbable VCDs are made from materials that the body can naturally break down and resorb, eliminating the need for a secondary procedure to remove the device. This characteristic is particularly beneficial for patients as it simplifies the post-procedural care and may lead to better long-term outcomes. Moreover, since there is nothing left behind in the body, the chances of chronic foreign body reactions are significantly reduced.

The development and utilization of these bioabsorbable devices are in line with the broader movement towards more biocompatible medical implants and represent the intersection of material science innovation with clinical application. As stakeholders in healthcare continue to prioritize patient safety and quality of care, bioabsorbable VCDs align well with these goals, helping to advance the standard of treatment in interventional cardiology.

These companies will likely benefit from the trend towards more biocompatible and patient-friendly medical devices. For market expansion, it's imperative to not only innovate but also to educate healthcare providers about the benefits and proper usage of these advanced devices. Moreover, regulatory clearances and favorable reimbursement scenarios will play pivotal roles in the adoption of bioabsorbable VCDs across various healthcare systems.

In summary, the emergence of bioabsorbable vascular closure devices is a key trend that stands to significantly impact the market by addressing patient comfort, reducing complications, and supporting the broader shift towards more minimally invasive and patient-friendly medical treatments.

• The adoption of hybrid closure procedures

The adoption of hybrid closure procedures is indeed an emerging trend that can drive the global vascular closure device market. Hybrid closure procedures involve the use of multiple techniques or devices to achieve efficient and secure closure of the arterial puncture site after cardiovascular This can include a combination of passive and active closure approaches or integrating different types of technologies to enhance the procedure's success rate and patient outcomes.

Hybrid procedures strive to combine the benefits of various closure methods to optimize hemostasis while minimizing the risk of vascular complications, such as bleeding or arterial occlusion. They are particularly significant for complex cases where a single-method approach may not be sufficiently effective or safe. For instance, a surgeon might use a VCD in conjunction with manual pressure or a topical hemostasis pad to ensure a blood-free and secure closure.

 This trend is driven by a continuous effort to improve patient care and reduce the cost burden of post-operative complications. As the healthcare industry progresses, there is a greater appreciation for personalized medicine, which involves tailoring medical treatments to the individual characteristics of each patient. Hybrid closure procedures can be seen as aligning with this philosophy, offering versatility to address varying patient anatomies and conditions.

Manufacturers are recognizing this trend and are likely to invest in product innovations that can cater to hybrid procedural approaches. By providing a suite of complementary products, companies can position themselves as complete solution providers rather than as vendors of a single device type. The rise of hybrid closure procedures highlights the need for ongoing research and training for clinicians to understand the nuances of various VCDs and their synergistic applications.

Moreover, with this trend gaining traction, the market has the potential for increased demand, encouraging further investment in the development and improvement of associated VCD technologies. Keeping an eye on this trend will be essential for market research, as the adoption of hybrid closure procedures represents both a significant opportunity for growth and a shift towards more comprehensive, patient-specific cardiovascular care.

Recent Developments

• In April 2025, Vivasure Medical, a leader in fully absorbable technology for minimally invasive vessel closure, announced that its PerQseal® Elite vascular closure system has received CE mark approval in Europe. This sutureless, fully bioresorbable device is designed for closing large-bore vessels, and the company intends to introduce it in select European markets later this summer.

• In September 2023, Boston Scientific Corporation, a medical device company, announced it had received U.S. Food and Drug Administration approval for the latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure (LAAC) Device.
• In September 2022, Haemonetics Corporation, a global medical technology company, announced it had earned Conformité Européenne (CE) mark certification for its VASCADE vascular closure and VASCADE MVP venous vascular closure systems. The CE marking will allow Haemonetics to engage in the next steps of country-specific entrance of both products into the European Union (EU) and form the basis for entry into other geographies that recognize CE marking.
• In May 2022, Teleflex Incorporated, a leading global provider of medical technologies, announced that it received Health Canada approval for the MANTA Vascular Closure Device, the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.
• In November 2023, Johnson & Johnson Service Inc., a biotechnology company, announced the completion of the acquisition of Laminar, Inc., a privately held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).

Market Segmentation

• By Product Type
• • Passive Vascular Closure Devices
  • Active Vascular Closure Devices
  • External Hemostatic Devices
• By Access
  • Femoral
  • Radial
• By Hole Size
  • Small Hole
  • Large Hole
• By End User
  • Hospitals
  • Ambulatory Surgery Centers
  • Others
• By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Top companies in Global Vascular Closure Device Market
  • Abbott
  • Cardiva Medical Inc.
  • Terumo Corporation
  • Johnson & Johnson Services Inc.
  • B. Braun SE
  • Biotronik SE & Co. KG
  • MicroPort Scientific Corporation
  • ConforMIS, Inc.
  • Medtronic
  • Transluminal Technologies LLC
  • Cardinal Health
  • Teleflex Incorporated
  • Vasorum Ltd.
  • Tricol Biomedical
  • Merit Medical Systems, Inc.
  • Stryker

Sources

Primary Research Interviews

• Vascular Surgeons
• Interventional Cardiologists
• Hospital Procurement Managers
• Medical Device Distributors
• Others

Databases

• BMI Research Healthcare Database
• Others

Magazines

• Medical Device Network
• Cardiovascular Business
• MedTech Dive
• Others

Journals

• Journal of the American College of Cardiology
• Circulation: Cardiovascular Interventions
• Journal of Vascular Surgery
• Others

Newspapers

• The Wall Street Journal (Health Section)
• Financial Times (Healthcare Edition)
• Others

Associations

• American Heart Association (AHA)
• Cardiovascular Research Foundation (CRF)
• Medical Device Manufacturers Association (MDMA)
• Others

Public Domain Sources

• U.S. FDA Medical Device Databases
• World Health Organization (WHO) Cardiovascular Disease Reports
• Centers for Medicare & Medicaid Services (CMS) Healthcare Data
• Others

 Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for Last 8 Years

N/A